Tenaya Therapeutics(TNYA) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Enrollment Complete in Cohorts 1 and 2 of MyPEAKTM-1 Phase 1b/2 Trial of TN-201 for MYBPC3- associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE™-1 Phase 1b Trial of TN-401 Enrolled and First PKP2-associated ARVC Patient Dosed in Cohort 2 Following DSMB Recommendation to Dose Escalate and Expand Data Readouts from Both TN-201 and TN-401 Clinical Program ...